Global Anti-idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027

By , in PR PR Health on .

LONDON, December 15, 2017

Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs

The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2016, the anti-fibrotics held the largest market share (52%) followed by the tyrosine kinase inhibitors.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 162-page report you will receive 57 tables and 97 figures– all unavailable elsewhere.

The 162-page report provides clear detailed insight into the global anti-idiopathic pulmonary fibrosis drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2027

• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action:
– Antifibrotics
– Tyrosine Kinase Inhibitors
– Anti-inflammatory Drugs
– Immunosuppressants
– Other MoA

• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs:
– Innovator Drugs
– Off-label Drugs

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– US
Japan
– EU5: Germany, France, the UK, Italy, Spain
– Rest of Europe
– Rest of World

• This report provides individual revenue forecasts to 2027 for these marketed drugs:
– Esbriet
– Ofev

• Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses:
– Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets (Historical 2010-2015, 2016 data, Forecast 2017-2027)
– Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity
– Epidemiology of Idiopathic Pulmonary Fibrosis by gender
– Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis
– Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS)
– A SWOT Analysis on the anti-idiopathic pulmonary fibrosis drugs market

• Our study discusses the marketed anti-idiopathic pulmonary fibrosis drugs and pipelineanti-idiopathic pulmonary fibrosis drugs from these companies:
– Actelion
– Afferent Pharmaceuticals
– Asahi Kasei Pharma
– Bellerophon Therapeutics
– Biogen
– Boehringer Ingelheim
– FibroGen
– Galapagos
– Galecto Biotech
– Genentech
– Global Blood Therapeutics
– GSK
– Kadmon Pharmaceuticals
– LTT Bio-Pharma
– MediciNova
– Merck
– Moerae
– Pacific Therapeutics
– Promedior
– ProMetic Life Sciences
– Roche
– Sanofi
– Teva
Zai Lab

Visiongain's study is intended for anyone requiring commercial analyses for the global Anti-Idiopathic Pulmonary Fibrosis Drugs Market. You find data, trends and predictions.

Buy our report today Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs.

To request a report overview of this report please contact Sara Peerun at [email protected] (+44-(0)-20-7336-6100) or refer to our website:

https://www.visiongain.com/Report/2085/Global-Anti-Idiopathic-Pulmonary-Fibrosis-Drugs-Market-Forecast-to-2027

List of Companies and Organizations Mentioned in the Report 

Actelion

Afferent Pharmaceuticals

American Thoracic Society (ATS)

Asahi Kasei Pharma

Auspex Pharmaceuticals

Bellerophon Therapeutics

Biogen Idec.

BMS

Boehringer Ingelheim

Canadian Agency for Drugs and Technologies in Health (CADTH) (Canada)

Curis

European Commission

European Respiratory Society (ERS)

FDA

FibroGen

Galapagos

Galecto

Genentech

Global Blood Therapeutics

Haute Autorité de Santé (HAS) (France)

Ikaria

Ildong Pharmaceutical Co., Ltd.

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (Germany)

IntelGenX

InterMune

Janssen

Japanese Respiratory Society (JRS)

Kadmon Corporation

Kadmon Holdings

Kedem Pharmaceuticals

Kyorin

Latin American Thoracic Association (ALAT)

LTT Bio-Pharma

MediciNova

Merck

MicroDose Therapeutx

Moerae Matrix

Nano Terra

National Institute for Health and Care Excellence (NICE)

Nippon Shinyaku

Pacific Therapeutics

Pharmaceutical Benefits Advisory Committee (PBAC) (Australia)

Pharmaxis

Promedior

ProMetic Life Sciences

Quintiles

Roche

Sanofi

Scottish Medicines Consortium (SMC) (Scotland)

Shionogi & Co., Ltd

Stromedix Inc.

Synairgen

Teva

Zai Lab

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain

The following two tabs change content below.
Brad Bennett

Brad Bennett

Brad grew up in a small town in northern Iowa. He studied chemistry in college, graduated, and married his wife one month later. They were then blessed with two baby boys within the first four years of marriage. Having babies gave their family a desire to return to the old paths – to nourish their family with traditional, homegrown foods; rid their home of toxic chemicals and petroleum products; and give their boys a chance to know a simple, sustainable way of life. They are currently building a homestead from scratch on two little acres in central Texas. There’s a lot to be done to become somewhat self-sufficient, but they are debt-free and get to spend their days living this simple, good life together with their five young children.
%d bloggers like this: